Literature DB >> 26629285

Glyxambi (Empagliflozin/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes.

Lisa A Raedler.   

Abstract

Entities:  

Year:  2015        PMID： 26629285      PMCID： PMC4665058     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  4 in total

1.  Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.

Authors:  Ralph A DeFronzo; Andrew Lewin; Sanjay Patel; Dacheng Liu; Renee Kaste; Hans J Woerle; Uli C Broedl
Journal:  Diabetes Care       Date:  2015-01-12       Impact factor: 19.112

2.  Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2015-01       Impact factor: 19.112

3.  10-year follow-up of intensive glucose control in type 2 diabetes.

Authors:  Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; David R Matthews; H Andrew W Neil
Journal:  N Engl J Med       Date:  2008-09-10       Impact factor: 91.245

4.  Economic costs of diabetes in the U.S. in 2012.

Authors: 
Journal:  Diabetes Care       Date:  2013-03-06       Impact factor: 19.112
  4 in total
  1 in total

1.  Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.

Authors:  Takashi Kadowaki; Nobuya Inagaki; Kazuoki Kondo; Kenichi Nishimura; Genki Kaneko; Nobuko Maruyama; Nobuhiro Nakanishi; Maki Gouda; Hiroaki Iijima; Yumi Watanabe
Journal:  Diabetes Obes Metab       Date:  2017-09-15       Impact factor: 6.577
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.